share_log

Wells Fargo Maintains Overweight on Acelyrin, Lowers Price Target to $13

Benzinga ·  Dec 11, 2024 23:05  · Ratings

Wells Fargo analyst Derek Archila maintains Acelyrin (NASDAQ:SLRN) with a Overweight and lowers the price target from $15 to $13.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment